Heptares raises GBP21M to finance pipeline

London, UK-based Heptares Therapeutics, a drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs),  has raised  GBP21.0 million ($30.6 million) of equity finance in a successful series A  private round from three blue-chip international venture capital firms.  Clarus Ventures led the syndicate, which includes the founding investor,  MVM Life Science Partners, and the Novartis Option Fund. All three  contributed equally.

Michael Steinmetz for Clarus Ventures and Anja Koenig for the Novartis  Option Fund have joined the Heptares board of directors as non-executive  directors.